Human cardiovascular effects of alprenolol, a beta-adrenergic blocker: hemodynamic, antiarrhythmic, and antianginal.
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use / Q000633:toxicity; D000328:Adult; D000605:Amino Alcohols / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy; D002302:Cardiac Output / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000188:drug therapy; D002986:Clinical Trials as Topic; D005260:Female; D006321:Heart / Q000187:drug effects; D006334:Heart Function Tests; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D010919:Placebos; D013565:Sympatholytics / Q000627:therapeutic use*; D013610:Tachycardia / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D010919:Placebos; D013565:Sympatholytics